Clinical Reviews in Allergy & Immunology

, Volume 32, Issue 3, pp 265–274

Clinical, Immunologic, and Molecular Factors Predicting Lymphoma Development in Sjogren’s Syndrome Patients

Article

Abstract

Among autoimmune diseases, Sjogren’s syndrome (SS) displays the highest incidence of non-Hodgkin lymphoma (NHL) development with the salivary extranodal marginal zone B cell lymphomas being the most common type. The majority of SS-associated NHLs are characterized by localized stage, indolent clinical course, and recurrence in other extranodal sites. Although the transition from a chronic inflammatory condition to malignant lymphoma is a multistep process yet poorly understood, there is increasing evidence that chronic antigenic stimulation by an exoantigen or autoantigens plays an essential role in the development of SS associated lymphoproliferation. Additional molecular oncogenic events such as microsatellite instability, loss of the B cell cycle control, and the forced overproduction of specific B cell biologic stimulators seem to contribute to the emergence and progression of the malignant overgrowth. Among the clinical and serological parameters that have been associated with lymphoma development in SS patients, the presence of palpable purpura, low C4, and mixed monoclonal cryoglobulinemia constitute the main predictive markers, and patients displaying these risk factors should be monitored closely.

Keywords

Sjogren’s syndrome Lymphoma Lymphoproliferation Predictive factors Prelymphomatous stage Autoimmunity 

References

  1. 1.
    Talal N, Bunim JJ (1964) The Development of Malignant Lymphoma in the Course of Sjoegren’s Syndrome. Am J Med 36:529–540CrossRefGoogle Scholar
  2. 2.
    Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888–892PubMedGoogle Scholar
  3. 3.
    Moutsopoulos HM, Steinberg AD, Fauci AS, Lane HC, Papadopoulos NM (1983) High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren’s syndrome. J Immunol 130:2663–2665PubMedGoogle Scholar
  4. 4.
    Tzioufas AG, Manoussakis MN, Costello R, Silis M, Papadopoulos NM, Moutsopoulos HM (1986) Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjogren’s syndrome. Arthritis Rheum 29:1098–1104PubMedCrossRefGoogle Scholar
  5. 5.
    Valesini G, Priori R, Bavoillot D, Osborn J, Danieli MG, Del Papa N et al (1997) Differential risk of non-Hodgkin’s lymphoma in Italian patients with primary Sjogren’s syndrome. J Rheumatol 24:2376–2380PubMedGoogle Scholar
  6. 6.
    Zulman J, Jaffe R, Talal N (1978) Evidence that the malignant lymphoma of Sjogren’s syndrome is a monoclonal B-cell neoplasm. N Engl J Med 299:1215–1220PubMedCrossRefGoogle Scholar
  7. 7.
    Schmid U, Helbron D, Lennert K (1982) Development of malignant lymphoma in myoepithelial sialadenitis (Sjogren’s syndrome). Virchows Arch A Pathol Anat Histol 395:11–43PubMedCrossRefGoogle Scholar
  8. 8.
    Pisa EK, Pisa P, Kang HI, Fox RI (1991) High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren’s syndrome patients. J Exp Med 174:1245–1250PubMedCrossRefGoogle Scholar
  9. 9.
    Sutcliffe N, Inanc M, Speight P, Isenberg D (1998) Predictors of lymphoma development in primary Sjogren’s syndrome. Semin Arthritis Rheum 28:80–87PubMedCrossRefGoogle Scholar
  10. 10.
    Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344PubMedCrossRefGoogle Scholar
  11. 11.
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum 42:1765–1772PubMedCrossRefGoogle Scholar
  12. 12.
    Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T et al (1997) Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90:766–775PubMedGoogle Scholar
  13. 13.
    Mariette X (1999) Lymphomas in patients with Sjogren’s syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 33(1–2):93–99PubMedGoogle Scholar
  14. 14.
    Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM (1991) Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol 96:738–745PubMedGoogle Scholar
  15. 15.
    Dogan A, Du M, Koulis A, Briskin MJ, Isaacson PG (1997) Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 151:1361–1369PubMedGoogle Scholar
  16. 16.
    Harris NL, Isaacson PG (1999) What are the criteria for distinguishing MALT from non-MALT lymphoma at extranodal sites? Am J Clin Pathol 111(1 Suppl 1):S126–S132PubMedGoogle Scholar
  17. 17.
    Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F et al (1999) Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 17:1254–1258PubMedGoogle Scholar
  18. 18.
    Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK et al (2003) Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 101:2489–2495PubMedCrossRefGoogle Scholar
  19. 19.
    Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P et al (2000) Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95(3):802–806PubMedGoogle Scholar
  20. 20.
    Rossi D, Gaidano G (2002) Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 7:239–252PubMedCrossRefGoogle Scholar
  21. 21.
    DiGiuseppe JA, Corio RL, Westa WH (1996) Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol 8:232–237PubMedCrossRefGoogle Scholar
  22. 22.
    Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C (1998) Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren’s syndrome. J Clin Invest 102:938–946PubMedGoogle Scholar
  23. 23.
    Adamson TC, Fox RI, Frisman DM, Howell FV (1983) Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies. J Immunol 130:203–208PubMedGoogle Scholar
  24. 24.
    Boumba D, Skopouli FN, Moutsopoulos HM (1995) Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren’s syndrome. Br J Rheumatol 34:326–333PubMedCrossRefGoogle Scholar
  25. 25.
    Moutsopoulos HM, Tzioufas AG, Bai MK, Papadopoulos NM, Papadimitriou CS (1990) Association of serum IgM kappa monoclonicity in patients with Sjogren’s syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands. Ann Rheum Dis 49:929–931PubMedGoogle Scholar
  26. 26.
    Freimark B, Fantozzi R, Bone R, Bordin G, Fox R (1989) Detection of clonally expanded salivary gland lymphocytes in Sjogren’s syndrome. Arthritis Rheum 32:859–869PubMedGoogle Scholar
  27. 27.
    Moutsopoulos HM, Costello R, Drosos AA, Mavridis AK, Papadopoulos NM (1985) Demonstration and identification of monoclonal proteins in the urine of patients with Sjogren’s syndrome. Ann Rheum Dis 44:109–112PubMedGoogle Scholar
  28. 28.
    Youinou P, Papadopoulos NM, Katsikis P, Pennec YL, Jouquan J, Lelong A et al (1988) Monoclonal immunoglobulins in the serum of patients with primary Sjogren’s syndrome. Clin Exp Rheumatol 6:247–252PubMedGoogle Scholar
  29. 29.
    Brito-Zeron P, Ramos-Casals M, Nardi N, Cervera R, Yague J, Ingelmo M et al (2005) Circulating monoclonal immunoglobulins in Sjogren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore) 84:90–97CrossRefGoogle Scholar
  30. 30.
    Bahler DW, Swerdlow SH (1998) Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren’s syndrome) begin as nonmalignant antigen-selected expansions. Blood 91:1864–1872PubMedGoogle Scholar
  31. 31.
    De Vita S, Boiocchi M, Sorrentino D, Carbone A, Avellini C, Dolcetti R et al (1997) Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren’s syndrome. Arthritis Rheum 40:318–331PubMedCrossRefGoogle Scholar
  32. 32.
    Harris NL (1999) Lymphoid proliferations of the salivary glands. Am J Clin Pathol 111(1 Suppl 1):S94–S103PubMedGoogle Scholar
  33. 33.
    Anaya JM, McGuff HS, Banks PM, Talal N (1996) Clinicopathological factors relating malignant lymphoma with Sjogren’s syndrome. Semin Arthritis Rheum 25:337–346PubMedCrossRefGoogle Scholar
  34. 34.
    Fong S, Chen PP, Gilbertson TA, Weber JR, Fox RI, Carson DA (1986) Expression of three cross-reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults. J Immunol 137:122–128PubMedGoogle Scholar
  35. 35.
    Fox RI, Chen P, Carson DA, Fong S (1986) Expression of a cross-reactive idiotype on rheumatoid factor in patients with Sjogren’s syndrome. J Immunol 136:477–483PubMedGoogle Scholar
  36. 36.
    Katsikis PD, Youinou PY, Galanopoulou V, Papadopoulos NM, Tzioufas AG, Moutsopoulos HM (1990) Monoclonal process in primary Sjogren’s syndrome and cross-reactive idiotype associated with rheumatoid factor. Clin Exp Immunol 82:509–514PubMedCrossRefGoogle Scholar
  37. 37.
    Bahler DW, Miklos JA, Swerdlow SH (1997) Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 89:3335–3344PubMedGoogle Scholar
  38. 38.
    Miklos JA, Swerdlow SH, Bahler DW (2000) Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 95:3878–3884PubMedGoogle Scholar
  39. 39.
    Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S et al (2000) Salivary gland lymphomas in patients with Sjogren’s syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43:908–916PubMedCrossRefGoogle Scholar
  40. 40.
    Hussell T, Isaacson PG, Crabtree JE, Dogan A, Spencer J (1993) Immunoglobulin specificity of low grade B cell gastrointestinal lymphoma of mucosa-associated lymphoid tissue (MALT) type. Am J Pathol 142:285–292PubMedGoogle Scholar
  41. 41.
    D’Elios MM, Manghetti M, Almerigogna F, Amedei A, Costa F, Burroni D et al (1997) Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol 27:1751–1755PubMedCrossRefGoogle Scholar
  42. 42.
    Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE et al (1998) Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity. Blood 92:3018–3024PubMedGoogle Scholar
  43. 43.
    Kong L, Ogawa N, Nakabayashi T, Liu GT, D’Souza E, McGuff HS et al (1997) Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 40:87–97PubMedCrossRefGoogle Scholar
  44. 44.
    Nakamura H, Kawakami A, Tominaga M, Migita K, Kawabe Y, Nakamura T et al (1999) Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren’s syndrome. Lab Invest 79:261–269PubMedGoogle Scholar
  45. 45.
    Bertolo F, De Vita S, Dolcetti R, Carbone A, Ferraccioli GF, Bartoli E, Boiocchi M (1999) Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjogren’s syndrome and type II mixed cryoglobulinemia. Clin Exp Rheumatol 17:339–342PubMedGoogle Scholar
  46. 46.
    Maes B, Baens M, Marynen P, De Wolf-Peeters C (2000) The product of the t(11;18), an API2-MLT fusion, is an almost exclusive finding in marginal zone cell lymphoma of extranodal MALT-type. Ann Oncol 1:521–526CrossRefGoogle Scholar
  47. 47.
    Du MQ, Isaccson PG (2002) Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3:97–104PubMedCrossRefGoogle Scholar
  48. 48.
    Raderer M, Osterreicher C, Machold K, Formanek M, Fiebiger W, Penz M et al (2001) Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease. Ann Oncol 12:937–939PubMedCrossRefGoogle Scholar
  49. 49.
    Streubel B, Huber D, Wohrer S, Chott A, Raderer M (2004) Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren’s syndrome. Clin Cancer Res 10:476–480PubMedCrossRefGoogle Scholar
  50. 50.
    Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697–1710PubMedCrossRefGoogle Scholar
  51. 51.
    Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T et al (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis 62:168–171PubMedCrossRefGoogle Scholar
  52. 52.
    Szodoray P, Jellestad S, Teague MO, Jonsson R (2003) Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren’s syndrome. Lab Invest 83:357–365PubMedCrossRefGoogle Scholar
  53. 53.
    Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y et al (2004) TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172:812–822PubMedGoogle Scholar
  54. 54.
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158PubMedCrossRefGoogle Scholar
  55. 55.
    Hsu SM, Waldron JW Jr, Hsu PL, Hough AJ Jr (1993) Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 24:1040–1057PubMedCrossRefGoogle Scholar
  56. 56.
    De Vita S, Dolcetti R, Ferraccioli G, Pivetta B, De Re V, Gloghini A, et al (1995) Local cytokine expression in the progression toward B cell malignancy in Sjogren’s syndrome. J Rheumatol 22:1674–1680PubMedGoogle Scholar
  57. 57.
    Peng H, Chen G, Du M, Singh N, Isaacson PG, Pan L (1996) Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue. Am J Pathol 148:643–648PubMedGoogle Scholar
  58. 58.
    Du M, Peng H, Singh N, Isaacson PG, Pan L (1995) The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587–4593PubMedGoogle Scholar
  59. 59.
    Soussi T (1996) The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 17:354–356PubMedCrossRefGoogle Scholar
  60. 60.
    Tapinos NI, Polihronis M, Moutsopoulos HM (1999) Lymphoma development in Sjogren’s syndrome: novel p53 mutations. Arthritis Rheum 42:1466–1472PubMedCrossRefGoogle Scholar
  61. 61.
    Kuppers R, Klein U, Hansmann ML, Rajewsky K (1999) Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520–1529PubMedCrossRefGoogle Scholar
  62. 62.
    Ihrler S, Baretton GB, Menauer F, Blasenbreu-Vogt S, Lohrs U (2000) Sjogren’s syndrome and MALT lymphomas of salivary glands: a DNA-cytometric and interphase-cytogenetic study. Mod Pathol 13:4–12PubMedCrossRefGoogle Scholar
  63. 63.
    Anderson LG, Talal N (1972) The spectrum of benign to malignant lymphoproliferation in Sjogren’s syndrome. Clin Exp Immunol 10:199–221PubMedGoogle Scholar
  64. 64.
    Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum 39:767–772PubMedCrossRefGoogle Scholar
  65. 65.
    Walters MT, Stevenson FK, Herbert A, Cawley MI, Smith JL (1986) Urinary monoclonal free light chains in primary Sjogren’s syndrome: an aid to the diagnosis of malignant lymphoma. Ann Rheum Dis 45:210–219PubMedCrossRefGoogle Scholar
  66. 66.
    Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sjogren’s syndrome. Semin Arthritis Rheum 29:296–304PubMedCrossRefGoogle Scholar
  67. 67.
    Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum 46:741–747PubMedCrossRefGoogle Scholar
  68. 68.
    Ramos-Casals M, Brito-Zeron P, Yague J, Akasbi M, Bautista R, Ruano M et al (2005) Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford) 44:89–94CrossRefGoogle Scholar
  69. 69.
    Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT (2006) Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796–803PubMedCrossRefGoogle Scholar
  70. 70.
    Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319PubMedCrossRefGoogle Scholar
  71. 71.
    Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 109:59–68PubMedCrossRefGoogle Scholar
  72. 72.
    Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A et al (2003) Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 48:1332–1342PubMedCrossRefGoogle Scholar
  73. 73.
    Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM (2001) Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjogren’s syndrome. Scand J Immunol 54:421–427PubMedCrossRefGoogle Scholar
  74. 74.
    Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J et al (2002) Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 46:2160–2171PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  1. 1.Department of Pathophysiology, Medical SchoolNational University of AthensAthensGreece
  2. 2.Department of Internal MedicineEuroclinic HospitalAthensGreece
  3. 3.Department of Dietetics and Nutritional ScienceHarokopio UniversityAthensGreece

Personalised recommendations